Health Care·Biotechnology·$2.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.52 | N/A | -47.86% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.52 | N/A | -47.86% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management acknowledged the challenges faced in the quarter. They emphasized their commitment to ongoing development efforts.
Management did not provide specific revenue guidance for the upcoming quarters.
The company is focused on advancing its pipeline despite the current financial results.
Sarepta Therapeutics reported a larger-than-expected loss per share, which contributed to a 2.23% decline in stock price. Investors may be concerned about the lack of revenue information and guidance. The company is focusing on its pipeline, but the financial results indicate ongoing challenges.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SIMON PPTY GROUP INC REIT
Aug 2, 2021